Iterum Therapeutics Announces Completion of Enrollment in its REASSURE Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections
24 oct. 2023 08h00 HE
|
Iterum Therapeutics PLC
– Topline Data Expected in Early Q1 2024 – – NDA Resubmission Expected in Q2 2024 – DUBLIN, Ireland and CHICAGO, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM)...
Iterum Therapeutics to Present Data at IDWeek 2023
12 oct. 2023 09h15 HE
|
Iterum Therapeutics PLC
DUBLIN, Ireland and CHICAGO, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics Reports Second Quarter 2023 Financial Results
11 août 2023 07h00 HE
|
Iterum Therapeutics PLC
--Expect to Complete Enrollment in Q1 2024; Topline Data Expected in Q2 2024 ----Cash Runway into Q3 2024-- DUBLIN, Ireland and CHICAGO, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc...
Iterum Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 11, 2023
04 août 2023 17h00 HE
|
Iterum Therapeutics PLC
DUBLIN, Ireland and CHICAGO, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics to Present Data at ASM Microbe 2023
12 juin 2023 18h23 HE
|
Iterum Therapeutics PLC
DUBLIN, Ireland and CHICAGO, June 12, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics Reports First Quarter 2023 Financial Results
12 mai 2023 07h00 HE
|
Iterum Therapeutics PLC
--Registration Trial for uUTI Ongoing and On Track-- --Cash Runway until Mid-2024-- DUBLIN, Ireland and CHICAGO, May 12, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum),...
Iterum Therapeutics Presents Scientific Posters at ECCMID 2023 Highlighting Application of Desirability of Outcomes Ranking (DOOR) to two Registration Trials
20 avr. 2023 17h00 HE
|
Iterum Therapeutics PLC
DUBLIN, Ireland and CHICAGO, April 20, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
16 mars 2023 07h00 HE
|
Iterum Therapeutics PLC
--Registration Trial for uUTI Ongoing and On Track----Cash Runway until Mid-2024-- --Company to host conference call today at 8:30amET-- DUBLIN, Ireland and CHICAGO, March 16, 2023 (GLOBE...
Iterum Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023
09 mars 2023 17h00 HE
|
Iterum Therapeutics PLC
DUBLIN, Ireland and CHICAGO, March 09, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics Reports Employment Inducement Grant
11 janv. 2023 18h00 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (“Iterum Therapeutics”), a clinical-stage pharmaceutical company focused on developing next...